LCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Lannett Company, Inc. and a Lead Plaintiff Deadline of January 17, 2017

NEW YORK, Nov. 25, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania on behalf of investors who purchased Lannett Company, Inc. LCI securities between September 12, 2013 and November 3, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/lannett-company. There is no cost or obligation to you.

According to the complaint, Lannett violated securities laws by virtue of its failure to disclose that Lannett's drug pricing relied on unsustainable pricing methodologies and that Lannett lacked effective internal controls concerning its drug pricing methodologies.

On July 16, 2014, Lannett revealed it had received interrogatories and a subpoena from the State of Connecticut Office of the Attorney General. By December 8, 2014, both the Company's Senior Vice President of Sales and Marketing and the Company were served grand jury subpoenas. On November 4, 2016, Bloomberg reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices.

If you suffered a loss in Lannett you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/lannett-company.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.